| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Helicobacter pylori | 298 | 2024 | 1295 | 48.590 |
Why?
|
| Helicobacter Infections | 262 | 2024 | 1216 | 42.990 |
Why?
|
| Antigens, Bacterial | 91 | 2023 | 354 | 14.030 |
Why?
|
| Bacterial Proteins | 110 | 2023 | 1029 | 13.480 |
Why?
|
| Gastric Mucosa | 80 | 2023 | 613 | 12.040 |
Why?
|
| Stomach Neoplasms | 101 | 2024 | 2278 | 11.640 |
Why?
|
| Virulence Factors | 51 | 2021 | 213 | 10.800 |
Why?
|
| Gastritis | 63 | 2022 | 373 | 10.290 |
Why?
|
| Drug Resistance, Bacterial | 33 | 2024 | 418 | 6.060 |
Why?
|
| Duodenal Ulcer | 22 | 2023 | 113 | 5.960 |
Why?
|
| Anti-Bacterial Agents | 54 | 2024 | 2992 | 5.650 |
Why?
|
| Peptic Ulcer | 26 | 2020 | 140 | 4.950 |
Why?
|
| Bacterial Outer Membrane Proteins | 29 | 2018 | 122 | 4.830 |
Why?
|
| Gastritis, Atrophic | 10 | 2023 | 81 | 4.600 |
Why?
|
| Antibodies, Bacterial | 22 | 2021 | 380 | 4.200 |
Why?
|
| Virulence | 35 | 2020 | 323 | 3.480 |
Why?
|
| Interleukin-8 | 25 | 2020 | 519 | 3.370 |
Why?
|
| Genes, Bacterial | 25 | 2021 | 236 | 3.360 |
Why?
|
| Genotype | 53 | 2020 | 4109 | 3.030 |
Why?
|
| Dyspepsia | 14 | 2022 | 103 | 2.870 |
Why?
|
| Stomach | 18 | 2023 | 387 | 2.810 |
Why?
|
| Stomach Ulcer | 14 | 2016 | 95 | 2.670 |
Why?
|
| DNA, Bacterial | 21 | 2020 | 558 | 2.540 |
Why?
|
| Adhesins, Bacterial | 12 | 2021 | 85 | 2.460 |
Why?
|
| Pepsinogen A | 8 | 2023 | 25 | 2.390 |
Why?
|
| Metaplasia | 11 | 2023 | 383 | 2.150 |
Why?
|
| Humans | 305 | 2024 | 261506 | 2.090 |
Why?
|
| Prevalence | 38 | 2021 | 3260 | 2.050 |
Why?
|
| Proton Pump Inhibitors | 15 | 2023 | 249 | 2.050 |
Why?
|
| Clarithromycin | 20 | 2024 | 119 | 2.040 |
Why?
|
| Levofloxacin | 10 | 2023 | 57 | 2.000 |
Why?
|
| Precancerous Conditions | 5 | 2021 | 1058 | 1.920 |
Why?
|
| Type IV Secretion Systems | 5 | 2022 | 7 | 1.880 |
Why?
|
| Microbial Sensitivity Tests | 21 | 2024 | 994 | 1.870 |
Why?
|
| Stomach Diseases | 7 | 2021 | 62 | 1.850 |
Why?
|
| Metronidazole | 16 | 2024 | 149 | 1.800 |
Why?
|
| Amoxicillin | 14 | 2024 | 106 | 1.790 |
Why?
|
| Host-Pathogen Interactions | 8 | 2019 | 314 | 1.720 |
Why?
|
| Indonesia | 10 | 2023 | 17 | 1.690 |
Why?
|
| Pepsinogen C | 4 | 2023 | 16 | 1.620 |
Why?
|
| Genomic Islands | 10 | 2023 | 32 | 1.590 |
Why?
|
| Japan | 21 | 2018 | 227 | 1.560 |
Why?
|
| Middle Aged | 126 | 2024 | 86204 | 1.530 |
Why?
|
| Duodenal Diseases | 4 | 2021 | 43 | 1.510 |
Why?
|
| Tetracycline | 8 | 2023 | 90 | 1.510 |
Why?
|
| Human Migration | 4 | 2019 | 13 | 1.490 |
Why?
|
| Bhutan | 13 | 2020 | 20 | 1.460 |
Why?
|
| Phylogeny | 20 | 2023 | 826 | 1.440 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2023 | 907 | 1.420 |
Why?
|
| Adult | 103 | 2023 | 77950 | 1.350 |
Why?
|
| Male | 143 | 2024 | 123000 | 1.350 |
Why?
|
| Cytokines | 11 | 2023 | 2809 | 1.350 |
Why?
|
| Young Adult | 45 | 2021 | 21445 | 1.210 |
Why?
|
| Female | 134 | 2024 | 141928 | 1.200 |
Why?
|
| Polymerase Chain Reaction | 33 | 2018 | 3203 | 1.190 |
Why?
|
| DNA Breaks, Double-Stranded | 4 | 2018 | 316 | 1.180 |
Why?
|
| Vietnam | 12 | 2021 | 56 | 1.180 |
Why?
|
| Aged | 86 | 2023 | 70117 | 1.180 |
Why?
|
| Drug Resistance, Microbial | 6 | 2023 | 218 | 1.120 |
Why?
|
| Polymorphism, Genetic | 12 | 2019 | 1450 | 1.100 |
Why?
|
| Interleukins | 6 | 2021 | 325 | 1.070 |
Why?
|
| Genome, Bacterial | 8 | 2021 | 200 | 1.060 |
Why?
|
| Drug Therapy, Combination | 20 | 2024 | 2315 | 1.030 |
Why?
|
| Atrophy | 6 | 2021 | 261 | 1.000 |
Why?
|
| Gastrointestinal Diseases | 7 | 2020 | 589 | 0.980 |
Why?
|
| Asia | 11 | 2023 | 142 | 0.980 |
Why?
|
| Interleukin-18 | 3 | 2009 | 100 | 0.960 |
Why?
|
| Adolescent | 42 | 2023 | 31252 | 0.940 |
Why?
|
| Epithelial Cells | 17 | 2021 | 1818 | 0.940 |
Why?
|
| Molecular Sequence Data | 28 | 2016 | 6089 | 0.900 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2023 | 202 | 0.900 |
Why?
|
| Aged, 80 and over | 47 | 2021 | 29902 | 0.880 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2021 | 1489 | 0.880 |
Why?
|
| Inflammation Mediators | 2 | 2019 | 423 | 0.860 |
Why?
|
| Biopsy | 17 | 2023 | 3443 | 0.850 |
Why?
|
| Inflammation | 7 | 2023 | 2522 | 0.850 |
Why?
|
| Omeprazole | 4 | 2020 | 92 | 0.830 |
Why?
|
| Pepsinogens | 2 | 2018 | 13 | 0.810 |
Why?
|
| Molecular Epidemiology | 8 | 2018 | 246 | 0.790 |
Why?
|
| Risk Factors | 26 | 2022 | 17523 | 0.790 |
Why?
|
| Colon, Transverse | 1 | 2020 | 8 | 0.760 |
Why?
|
| Mongolia | 5 | 2021 | 7 | 0.750 |
Why?
|
| Nepal | 5 | 2019 | 11 | 0.750 |
Why?
|
| Emigration and Immigration | 6 | 2011 | 86 | 0.740 |
Why?
|
| Agar | 1 | 2020 | 26 | 0.740 |
Why?
|
| Genomic Instability | 4 | 2018 | 519 | 0.730 |
Why?
|
| Mutation | 20 | 2022 | 15179 | 0.730 |
Why?
|
| Phylogeography | 3 | 2019 | 16 | 0.720 |
Why?
|
| RNA, Ribosomal, 23S | 6 | 2023 | 26 | 0.720 |
Why?
|
| RNA, Messenger | 17 | 2017 | 6150 | 0.720 |
Why?
|
| Hydrogen-Ion Concentration | 12 | 2019 | 585 | 0.710 |
Why?
|
| Colitis | 1 | 2023 | 340 | 0.700 |
Why?
|
| Interleukin-17 | 4 | 2021 | 250 | 0.690 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 170 | 0.680 |
Why?
|
| Conjugation, Genetic | 1 | 2018 | 10 | 0.680 |
Why?
|
| Thailand | 9 | 2021 | 32 | 0.670 |
Why?
|
| Cytochrome P-450 CYP2C19 | 5 | 2019 | 22 | 0.670 |
Why?
|
| Acids | 2 | 2017 | 38 | 0.670 |
Why?
|
| Incidence | 12 | 2020 | 5673 | 0.660 |
Why?
|
| Pasteurellaceae Infections | 1 | 2018 | 1 | 0.650 |
Why?
|
| Gastroscopy | 9 | 2017 | 134 | 0.650 |
Why?
|
| Aggregatibacter actinomycetemcomitans | 1 | 2018 | 4 | 0.650 |
Why?
|
| Palliative Care | 3 | 2014 | 2037 | 0.640 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 363 | 0.630 |
Why?
|
| Anti-Ulcer Agents | 6 | 2009 | 101 | 0.630 |
Why?
|
| Bangladesh | 4 | 2019 | 24 | 0.630 |
Why?
|
| Sequence Analysis, DNA | 15 | 2018 | 2483 | 0.620 |
Why?
|
| Gerbillinae | 11 | 2021 | 52 | 0.620 |
Why?
|
| Genetic Variation | 9 | 2015 | 2086 | 0.620 |
Why?
|
| Toll-Like Receptors | 1 | 2019 | 174 | 0.620 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 4314 | 0.620 |
Why?
|
| Amino Acid Sequence | 16 | 2019 | 4233 | 0.620 |
Why?
|
| Sensitivity and Specificity | 10 | 2022 | 4971 | 0.600 |
Why?
|
| Microbial Viability | 1 | 2017 | 62 | 0.590 |
Why?
|
| Gastroesophageal Reflux | 3 | 2020 | 334 | 0.590 |
Why?
|
| Endoscopy | 8 | 2018 | 479 | 0.590 |
Why?
|
| Myanmar | 4 | 2018 | 9 | 0.590 |
Why?
|
| Breath Tests | 7 | 2022 | 177 | 0.580 |
Why?
|
| Urea | 7 | 2022 | 290 | 0.580 |
Why?
|
| Bacterial Adhesion | 10 | 2021 | 147 | 0.560 |
Why?
|
| Islands | 1 | 2015 | 2 | 0.560 |
Why?
|
| Biomarkers | 8 | 2021 | 5047 | 0.550 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 60 | 0.550 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 246 | 0.550 |
Why?
|
| Interleukin-6 | 4 | 2011 | 1038 | 0.550 |
Why?
|
| Colombia | 7 | 2014 | 66 | 0.540 |
Why?
|
| Home Care Services | 2 | 2014 | 92 | 0.540 |
Why?
|
| Africa | 9 | 2022 | 142 | 0.540 |
Why?
|
| Kallikreins | 1 | 2016 | 84 | 0.530 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 461 | 0.520 |
Why?
|
| Autophagy | 2 | 2023 | 927 | 0.520 |
Why?
|
| Exercise | 1 | 2023 | 1183 | 0.520 |
Why?
|
| Odds Ratio | 10 | 2013 | 2316 | 0.510 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2020 | 2359 | 0.510 |
Why?
|
| Rad51 Recombinase | 1 | 2015 | 126 | 0.510 |
Why?
|
| Geography | 8 | 2015 | 140 | 0.500 |
Why?
|
| Immunoblotting | 6 | 2011 | 886 | 0.490 |
Why?
|
| Microbiota | 2 | 2020 | 547 | 0.490 |
Why?
|
| Population Surveillance | 1 | 2018 | 627 | 0.490 |
Why?
|
| Urease | 5 | 2022 | 60 | 0.470 |
Why?
|
| Actins | 3 | 2012 | 608 | 0.470 |
Why?
|
| Base Sequence | 13 | 2016 | 4917 | 0.470 |
Why?
|
| Stress, Physiological | 1 | 2017 | 492 | 0.460 |
Why?
|
| Gene Expression Regulation, Bacterial | 7 | 2021 | 192 | 0.460 |
Why?
|
| Pyloric Antrum | 7 | 2018 | 60 | 0.460 |
Why?
|
| Homologous Recombination | 1 | 2014 | 185 | 0.460 |
Why?
|
| Intestines | 1 | 2018 | 686 | 0.450 |
Why?
|
| Age Distribution | 7 | 2015 | 698 | 0.450 |
Why?
|
| Phosphorylation | 12 | 2020 | 4804 | 0.450 |
Why?
|
| Transcription Factor AP-1 | 4 | 2007 | 246 | 0.450 |
Why?
|
| Bacterial Typing Techniques | 2 | 2011 | 139 | 0.440 |
Why?
|
| Latex Fixation Tests | 2 | 2023 | 10 | 0.440 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2014 | 132 | 0.440 |
Why?
|
| Cell Line | 15 | 2020 | 5114 | 0.430 |
Why?
|
| Lactic Acid | 1 | 2014 | 305 | 0.430 |
Why?
|
| Cytotoxins | 2 | 2023 | 66 | 0.430 |
Why?
|
| Immunohistochemistry | 10 | 2020 | 7548 | 0.420 |
Why?
|
| Multilocus Sequence Typing | 5 | 2020 | 58 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2023 | 4549 | 0.420 |
Why?
|
| Mutagenesis, Insertional | 1 | 2013 | 218 | 0.420 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 1390 | 0.420 |
Why?
|
| Interleukin-11 | 1 | 2011 | 37 | 0.410 |
Why?
|
| Prostate-Specific Antigen | 1 | 2016 | 993 | 0.410 |
Why?
|
| Sequence Deletion | 3 | 2009 | 875 | 0.410 |
Why?
|
| Hypertension | 3 | 2023 | 1503 | 0.410 |
Why?
|
| Paxillin | 1 | 2011 | 30 | 0.410 |
Why?
|
| Glycosyltransferases | 1 | 2011 | 34 | 0.400 |
Why?
|
| ErbB Receptors | 2 | 2011 | 2295 | 0.400 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2012 | 1678 | 0.390 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2008 | 161 | 0.390 |
Why?
|
| Hospice Care | 1 | 2012 | 156 | 0.390 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2011 | 80 | 0.390 |
Why?
|
| Animals | 37 | 2023 | 59536 | 0.390 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 3 | 2001 | 362 | 0.390 |
Why?
|
| Promoter Regions, Genetic | 8 | 2008 | 3101 | 0.390 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2011 | 111 | 0.380 |
Why?
|
| Interleukin-1 | 6 | 2005 | 461 | 0.380 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2011 | 46 | 0.380 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2010 | 9 | 0.380 |
Why?
|
| Kidney Failure, Chronic | 2 | 2009 | 960 | 0.380 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2010 | 26 | 0.370 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2023 | 490 | 0.370 |
Why?
|
| Microarray Analysis | 4 | 2017 | 392 | 0.370 |
Why?
|
| Adaptation, Physiological | 3 | 2021 | 360 | 0.370 |
Why?
|
| Transcriptional Activation | 4 | 2014 | 1070 | 0.370 |
Why?
|
| Multigene Family | 1 | 2011 | 425 | 0.370 |
Why?
|
| Biofilms | 2 | 2023 | 199 | 0.360 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2017 | 2291 | 0.360 |
Why?
|
| Genetic Markers | 6 | 2020 | 974 | 0.360 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 3 | 2022 | 301 | 0.350 |
Why?
|
| Interleukin-1beta | 3 | 2018 | 300 | 0.350 |
Why?
|
| Gene Expression Profiling | 4 | 2017 | 5159 | 0.350 |
Why?
|
| Chronic Disease | 3 | 2020 | 1819 | 0.340 |
Why?
|
| Endoscopy, Gastrointestinal | 6 | 2024 | 375 | 0.340 |
Why?
|
| Public Health | 1 | 2011 | 299 | 0.330 |
Why?
|
| Phosphotyrosine | 4 | 2016 | 111 | 0.330 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 787 | 0.320 |
Why?
|
| DNA Primers | 6 | 2013 | 1399 | 0.320 |
Why?
|
| DNA Gyrase | 2 | 2019 | 24 | 0.320 |
Why?
|
| Bacterial Toxins | 2 | 2008 | 228 | 0.320 |
Why?
|
| NF-kappa B | 8 | 2015 | 1549 | 0.320 |
Why?
|
| Biomarkers, Tumor | 3 | 2018 | 10331 | 0.320 |
Why?
|
| Case-Control Studies | 8 | 2020 | 6100 | 0.320 |
Why?
|
| Gene Expression Regulation | 8 | 2013 | 4053 | 0.310 |
Why?
|
| Chemokine CCL5 | 2 | 2005 | 71 | 0.310 |
Why?
|
| Phenotype | 11 | 2020 | 6295 | 0.310 |
Why?
|
| Duodenum | 1 | 2008 | 149 | 0.300 |
Why?
|
| Evolution, Molecular | 5 | 2019 | 834 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2012 | 2054 | 0.300 |
Why?
|
| Predictive Value of Tests | 7 | 2016 | 4892 | 0.300 |
Why?
|
| DNA Repair | 2 | 2016 | 1872 | 0.300 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 778 | 0.300 |
Why?
|
| Cell Line, Tumor | 13 | 2021 | 14551 | 0.290 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2007 | 161 | 0.290 |
Why?
|
| Signal Transduction | 13 | 2016 | 11965 | 0.290 |
Why?
|
| Seroepidemiologic Studies | 4 | 2013 | 129 | 0.290 |
Why?
|
| ROC Curve | 2 | 2020 | 1183 | 0.280 |
Why?
|
| Cytoskeleton | 1 | 2007 | 267 | 0.280 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2006 | 58 | 0.280 |
Why?
|
| Dominican Republic | 7 | 2020 | 18 | 0.280 |
Why?
|
| DNA-Directed RNA Polymerases | 3 | 2019 | 97 | 0.270 |
Why?
|
| Transformation, Bacterial | 3 | 2015 | 16 | 0.270 |
Why?
|
| Chi-Square Distribution | 4 | 2013 | 1323 | 0.270 |
Why?
|
| Genome-Wide Association Study | 3 | 2021 | 2265 | 0.260 |
Why?
|
| Adenocarcinoma | 6 | 2016 | 7789 | 0.260 |
Why?
|
| Risk Assessment | 7 | 2015 | 6869 | 0.260 |
Why?
|
| DNA Restriction Enzymes | 1 | 2004 | 117 | 0.250 |
Why?
|
| Treatment Failure | 3 | 2023 | 1391 | 0.250 |
Why?
|
| Renal Dialysis | 2 | 2010 | 945 | 0.250 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 1225 | 0.250 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 14889 | 0.250 |
Why?
|
| Time Factors | 10 | 2017 | 12926 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 5437 | 0.250 |
Why?
|
| Prognosis | 8 | 2023 | 21713 | 0.250 |
Why?
|
| Cells, Cultured | 7 | 2019 | 5637 | 0.250 |
Why?
|
| Bacteriocins | 1 | 2023 | 5 | 0.240 |
Why?
|
| Lactococcus lactis | 1 | 2023 | 5 | 0.240 |
Why?
|
| Transcription Factors | 3 | 2008 | 5270 | 0.240 |
Why?
|
| United States | 11 | 2022 | 15433 | 0.240 |
Why?
|
| Adenomatous Polyps | 1 | 2024 | 45 | 0.240 |
Why?
|
| Asia, Southeastern | 3 | 2018 | 23 | 0.230 |
Why?
|
| Point Mutation | 2 | 2016 | 769 | 0.230 |
Why?
|
| Mycobacterium abscessus | 1 | 2023 | 13 | 0.230 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 4320 | 0.230 |
Why?
|
| Up-Regulation | 8 | 2017 | 2450 | 0.230 |
Why?
|
| Fluoroquinolones | 3 | 2019 | 126 | 0.230 |
Why?
|
| Treatment Outcome | 13 | 2023 | 32848 | 0.230 |
Why?
|
| Polyps | 1 | 2024 | 74 | 0.230 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2023 | 17 | 0.220 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 1870 | 0.220 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 215 | 0.220 |
Why?
|
| Carbon Radioisotopes | 2 | 2022 | 116 | 0.220 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2023 | 82 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 2403 | 0.220 |
Why?
|
| Oncogene Proteins | 2 | 2021 | 354 | 0.210 |
Why?
|
| Disease Eradication | 2 | 2019 | 36 | 0.210 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2022 | 78 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 10035 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2017 | 5539 | 0.200 |
Why?
|
| Iran | 8 | 2018 | 68 | 0.200 |
Why?
|
| Interleukin-23 | 1 | 2021 | 29 | 0.200 |
Why?
|
| Biological Transport | 1 | 2023 | 597 | 0.200 |
Why?
|
| RNA, Small Untranslated | 1 | 2021 | 29 | 0.200 |
Why?
|
| RNA, Bacterial | 1 | 2021 | 80 | 0.200 |
Why?
|
| Isoenzymes | 1 | 2003 | 614 | 0.200 |
Why?
|
| Logistic Models | 3 | 2013 | 3441 | 0.190 |
Why?
|
| Genetics, Population | 2 | 2018 | 242 | 0.190 |
Why?
|
| Sequence Alignment | 6 | 2016 | 844 | 0.190 |
Why?
|
| Kenya | 1 | 2020 | 46 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 2594 | 0.190 |
Why?
|
| Receptors, LDL | 1 | 2021 | 109 | 0.190 |
Why?
|
| Lipoproteins, LDL | 1 | 2021 | 163 | 0.190 |
Why?
|
| Cambodia | 1 | 2020 | 12 | 0.190 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2022 | 203 | 0.190 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 264 | 0.190 |
Why?
|
| Age Factors | 6 | 2015 | 5377 | 0.190 |
Why?
|
| Polymorphism, Restriction Fragment Length | 4 | 2015 | 239 | 0.190 |
Why?
|
| Prospective Studies | 7 | 2024 | 12873 | 0.190 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 3230 | 0.190 |
Why?
|
| MicroRNAs | 1 | 2014 | 2947 | 0.180 |
Why?
|
| Gene Frequency | 3 | 2015 | 1163 | 0.180 |
Why?
|
| Biodiversity | 1 | 2020 | 91 | 0.180 |
Why?
|
| 3' Untranslated Regions | 1 | 2001 | 343 | 0.180 |
Why?
|
| Retrospective Studies | 10 | 2023 | 37905 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2015 | 1538 | 0.180 |
Why?
|
| Carcinogenesis | 2 | 2023 | 1026 | 0.170 |
Why?
|
| Gastric Acid | 2 | 2009 | 42 | 0.170 |
Why?
|
| Gastrectomy | 2 | 2020 | 451 | 0.170 |
Why?
|
| Amino Acid Motifs | 6 | 2020 | 392 | 0.170 |
Why?
|
| Furazolidone | 1 | 2019 | 7 | 0.170 |
Why?
|
| Prophages | 1 | 2019 | 6 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 527 | 0.170 |
Why?
|
| Peptide Mapping | 1 | 2019 | 114 | 0.170 |
Why?
|
| Rifabutin | 1 | 2019 | 25 | 0.170 |
Why?
|
| Cluster Analysis | 2 | 2014 | 1053 | 0.170 |
Why?
|
| Tight Junctions | 1 | 2019 | 56 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 3639 | 0.170 |
Why?
|
| Bias | 1 | 2020 | 205 | 0.170 |
Why?
|
| Tyrosine | 1 | 2020 | 498 | 0.170 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 7222 | 0.170 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 2927 | 0.170 |
Why?
|
| Recombination, Genetic | 3 | 2019 | 613 | 0.160 |
Why?
|
| Chemotactic Factors | 1 | 1998 | 42 | 0.160 |
Why?
|
| Cross Infection | 1 | 2023 | 544 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2020 | 285 | 0.160 |
Why?
|
| Antigens, Neoplasm | 2 | 2015 | 1506 | 0.160 |
Why?
|
| Lasers, Semiconductor | 1 | 2018 | 14 | 0.160 |
Why?
|
| 3' Flanking Region | 1 | 2018 | 9 | 0.160 |
Why?
|
| Interferon-gamma | 4 | 2013 | 1144 | 0.160 |
Why?
|
| Kefir | 1 | 2017 | 4 | 0.160 |
Why?
|
| Immunoglobulin G | 4 | 2010 | 1021 | 0.160 |
Why?
|
| GPI-Linked Proteins | 2 | 2015 | 223 | 0.160 |
Why?
|
| Freeze Drying | 1 | 2017 | 30 | 0.160 |
Why?
|
| DNA | 3 | 2023 | 2693 | 0.160 |
Why?
|
| Chemokines, CXC | 1 | 1998 | 117 | 0.160 |
Why?
|
| Genitalia, Male | 1 | 2017 | 36 | 0.160 |
Why?
|
| Fermentation | 1 | 2017 | 60 | 0.160 |
Why?
|
| Developing Countries | 1 | 2020 | 315 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2017 | 1217 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2023 | 340 | 0.150 |
Why?
|
| Apoptosis | 3 | 2020 | 7591 | 0.150 |
Why?
|
| Lymph Nodes | 2 | 2020 | 2967 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 2283 | 0.150 |
Why?
|
| Growth Substances | 1 | 1998 | 300 | 0.150 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2016 | 2 | 0.150 |
Why?
|
| Death | 1 | 2018 | 119 | 0.150 |
Why?
|
| Prokaryotic Initiation Factor-2 | 1 | 2016 | 1 | 0.150 |
Why?
|
| Lymph Node Excision | 3 | 2020 | 1959 | 0.150 |
Why?
|
| Nitroreductases | 1 | 2016 | 6 | 0.150 |
Why?
|
| Volunteers | 1 | 2017 | 29 | 0.150 |
Why?
|
| Duodenoscopy | 1 | 2016 | 18 | 0.150 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 338 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 966 | 0.150 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2016 | 128 | 0.150 |
Why?
|
| Oligosaccharides | 1 | 2017 | 110 | 0.150 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 489 | 0.150 |
Why?
|
| Nucleotides | 1 | 2017 | 164 | 0.150 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2008 | 194 | 0.140 |
Why?
|
| Epitopes | 1 | 2019 | 685 | 0.140 |
Why?
|
| Histamine H2 Antagonists | 2 | 2009 | 50 | 0.140 |
Why?
|
| Transcription, Genetic | 4 | 2008 | 3154 | 0.140 |
Why?
|
| Protoporphyrins | 1 | 2016 | 10 | 0.140 |
Why?
|
| Korea | 3 | 2009 | 63 | 0.140 |
Why?
|
| Constipation | 1 | 2017 | 177 | 0.140 |
Why?
|
| Oxidative Stress | 1 | 2023 | 1129 | 0.140 |
Why?
|
| Disease Progression | 2 | 2021 | 6682 | 0.140 |
Why?
|
| Aminolevulinic Acid | 1 | 2016 | 19 | 0.140 |
Why?
|
| Neoplasms | 4 | 2017 | 15193 | 0.140 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 1258 | 0.140 |
Why?
|
| Sanitation | 1 | 2015 | 14 | 0.140 |
Why?
|
| Frameshift Mutation | 1 | 2016 | 220 | 0.140 |
Why?
|
| Culture Techniques | 2 | 2014 | 132 | 0.140 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 2006 | 47 | 0.140 |
Why?
|
| Photosensitizing Agents | 1 | 2016 | 71 | 0.140 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 138 | 0.140 |
Why?
|
| Hepatocytes | 2 | 2008 | 351 | 0.140 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2016 | 209 | 0.130 |
Why?
|
| Toll-Like Receptor 10 | 1 | 2015 | 2 | 0.130 |
Why?
|
| Bacteria | 1 | 2020 | 611 | 0.130 |
Why?
|
| Taiwan | 4 | 2023 | 93 | 0.130 |
Why?
|
| Vagina | 1 | 2017 | 317 | 0.130 |
Why?
|
| Disease Susceptibility | 3 | 2017 | 538 | 0.130 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2008 | 334 | 0.130 |
Why?
|
| Sunbathing | 1 | 2015 | 10 | 0.130 |
Why?
|
| PUVA Therapy | 1 | 2015 | 34 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 3472 | 0.130 |
Why?
|
| Protein Array Analysis | 2 | 2009 | 501 | 0.130 |
Why?
|
| Light | 1 | 2016 | 245 | 0.130 |
Why?
|
| Genes | 1 | 1996 | 491 | 0.130 |
Why?
|
| Genomics | 2 | 2023 | 2738 | 0.130 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2006 | 182 | 0.130 |
Why?
|
| Epithelium | 1 | 2017 | 720 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 4298 | 0.130 |
Why?
|
| Bacterial Secretion Systems | 1 | 2014 | 2 | 0.130 |
Why?
|
| Diet | 2 | 2022 | 1440 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1998 | 650 | 0.130 |
Why?
|
| Immune Evasion | 1 | 2015 | 73 | 0.120 |
Why?
|
| Asthma | 1 | 2022 | 871 | 0.120 |
Why?
|
| Serial Passage | 1 | 2014 | 15 | 0.120 |
Why?
|
| Saponins | 2 | 1991 | 34 | 0.120 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 275 | 0.120 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2007 | 460 | 0.120 |
Why?
|
| Cross Reactions | 2 | 2012 | 266 | 0.120 |
Why?
|
| HeLa Cells | 1 | 2018 | 1643 | 0.120 |
Why?
|
| Demography | 1 | 2015 | 435 | 0.120 |
Why?
|
| Psoriasis | 1 | 2015 | 126 | 0.120 |
Why?
|
| Latin America | 2 | 2017 | 115 | 0.120 |
Why?
|
| DNA, Ribosomal | 1 | 2014 | 103 | 0.120 |
Why?
|
| Pyrroles | 1 | 2018 | 576 | 0.120 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2013 | 20 | 0.120 |
Why?
|
| Plants, Medicinal | 2 | 1990 | 44 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 1054 | 0.120 |
Why?
|
| Feces | 2 | 2016 | 770 | 0.120 |
Why?
|
| Duodenitis | 1 | 2013 | 15 | 0.120 |
Why?
|
| Consensus | 1 | 2018 | 978 | 0.120 |
Why?
|
| Neutrophils | 3 | 2009 | 835 | 0.120 |
Why?
|
| Standard of Care | 1 | 2015 | 243 | 0.120 |
Why?
|
| src-Family Kinases | 3 | 2016 | 478 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2014 | 189 | 0.110 |
Why?
|
| Coculture Techniques | 3 | 2015 | 626 | 0.110 |
Why?
|
| Phospholipases A1 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 1046 | 0.110 |
Why?
|
| Drug Design | 1 | 2015 | 375 | 0.110 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 1995 | 128 | 0.110 |
Why?
|
| Community Networks | 1 | 2012 | 45 | 0.110 |
Why?
|
| Health Services for the Aged | 1 | 2012 | 50 | 0.110 |
Why?
|
| DNA Replication | 1 | 2016 | 744 | 0.110 |
Why?
|
| Intestinal Mucosa | 2 | 2011 | 1081 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2021 | 2216 | 0.110 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2014 | 430 | 0.110 |
Why?
|
| Models, Biological | 2 | 2018 | 3254 | 0.110 |
Why?
|
| Population | 1 | 2011 | 27 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2014 | 481 | 0.100 |
Why?
|
| Th17 Cells | 1 | 2013 | 162 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2012 | 79 | 0.100 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2012 | 113 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2016 | 803 | 0.100 |
Why?
|
| Immunoprecipitation | 2 | 2016 | 591 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2014 | 829 | 0.100 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2012 | 167 | 0.100 |
Why?
|
| Health Surveys | 1 | 2013 | 402 | 0.100 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2008 | 163 | 0.100 |
Why?
|
| Serologic Tests | 2 | 2003 | 137 | 0.100 |
Why?
|
| Trophoblasts | 1 | 2012 | 138 | 0.100 |
Why?
|
| Renin-Angiotensin System | 1 | 2012 | 103 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 551 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 450 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2007 | 2508 | 0.100 |
Why?
|
| Colony Count, Microbial | 3 | 2018 | 149 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2016 | 1152 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 481 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 4744 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 2 | 2018 | 769 | 0.100 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2010 | 12 | 0.100 |
Why?
|
| Esophageal Neoplasms | 2 | 2024 | 3168 | 0.100 |
Why?
|
| Dust | 1 | 2010 | 39 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 945 | 0.090 |
Why?
|
| Bismuth | 2 | 2023 | 75 | 0.090 |
Why?
|
| Blood Group Antigens | 1 | 2011 | 90 | 0.090 |
Why?
|
| Residence Characteristics | 1 | 2013 | 348 | 0.090 |
Why?
|
| Celiac Disease | 1 | 2011 | 75 | 0.090 |
Why?
|
| Pollen | 1 | 2010 | 47 | 0.090 |
Why?
|
| Obesity | 1 | 2023 | 2884 | 0.090 |
Why?
|
| Europe | 4 | 2012 | 649 | 0.090 |
Why?
|
| Research Design | 2 | 2008 | 1544 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2012 | 1062 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2020 | 9244 | 0.090 |
Why?
|
| Global Health | 2 | 2020 | 657 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2010 | 163 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 78 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 13658 | 0.090 |
Why?
|
| Middle East | 1 | 2009 | 46 | 0.090 |
Why?
|
| Pre-Eclampsia | 1 | 2012 | 212 | 0.090 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2009 | 82 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 1202 | 0.090 |
Why?
|
| DNA Fingerprinting | 1 | 2009 | 167 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2009 | 185 | 0.090 |
Why?
|
| Risk | 1 | 2014 | 1972 | 0.090 |
Why?
|
| Smoking | 1 | 2018 | 2440 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2012 | 611 | 0.090 |
Why?
|
| Hospitals | 1 | 2012 | 485 | 0.090 |
Why?
|
| Oxidoreductases | 2 | 2021 | 171 | 0.080 |
Why?
|
| Environmental Microbiology | 1 | 2009 | 22 | 0.080 |
Why?
|
| Chemokine CCL20 | 1 | 2008 | 39 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2018 | 1823 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2017 | 2022 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 703 | 0.080 |
Why?
|
| Cadherins | 2 | 2015 | 660 | 0.080 |
Why?
|
| India | 1 | 2009 | 301 | 0.080 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2008 | 20 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2016 | 1756 | 0.080 |
Why?
|
| B7-H1 Antigen | 1 | 2015 | 1022 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2010 | 495 | 0.080 |
Why?
|
| HIV Infections | 1 | 2020 | 2134 | 0.080 |
Why?
|
| Microsatellite Repeats | 2 | 1999 | 575 | 0.080 |
Why?
|
| Dimerization | 1 | 2008 | 304 | 0.080 |
Why?
|
| United Kingdom | 1 | 2008 | 257 | 0.080 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2007 | 11 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 2008 | 5395 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2012 | 795 | 0.070 |
Why?
|
| Endocytosis | 1 | 2008 | 225 | 0.070 |
Why?
|
| E2F Transcription Factors | 1 | 2007 | 132 | 0.070 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2008 | 190 | 0.070 |
Why?
|
| Interleukin-12 | 1 | 2008 | 253 | 0.070 |
Why?
|
| Gene Expression | 3 | 2004 | 3570 | 0.070 |
Why?
|
| Decision Making | 1 | 2014 | 1287 | 0.070 |
Why?
|
| Models, Genetic | 2 | 2008 | 1113 | 0.070 |
Why?
|
| Interferon Regulatory Factors | 1 | 2007 | 76 | 0.070 |
Why?
|
| Luciferases | 1 | 2008 | 445 | 0.070 |
Why?
|
| DNA, Mitochondrial | 2 | 2019 | 311 | 0.070 |
Why?
|
| Mucins | 1 | 2008 | 285 | 0.070 |
Why?
|
| Morbidity | 1 | 2008 | 397 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 702 | 0.070 |
Why?
|
| Drug Costs | 1 | 2008 | 144 | 0.070 |
Why?
|
| I-kappa B Proteins | 1 | 2007 | 170 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2008 | 1620 | 0.070 |
Why?
|
| raf Kinases | 1 | 2006 | 81 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2006 | 123 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1990 | 852 | 0.070 |
Why?
|
| Sulfoxides | 1 | 2005 | 22 | 0.070 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2006 | 79 | 0.070 |
Why?
|
| Medical Records | 1 | 2007 | 415 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 931 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2009 | 6009 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2006 | 166 | 0.070 |
Why?
|
| Esomeprazole | 1 | 2005 | 31 | 0.070 |
Why?
|
| Laos | 2 | 2016 | 6 | 0.070 |
Why?
|
| Citric Acid | 2 | 2004 | 54 | 0.060 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 132 | 0.060 |
Why?
|
| Western World | 1 | 2004 | 8 | 0.060 |
Why?
|
| Nontherapeutic Human Experimentation | 1 | 2004 | 7 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2004 | 151 | 0.060 |
Why?
|
| Malaysia | 2 | 2018 | 20 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 170 | 0.060 |
Why?
|
| Pacific Islands | 2 | 2017 | 6 | 0.060 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2004 | 53 | 0.060 |
Why?
|
| Threonine | 1 | 2004 | 161 | 0.060 |
Why?
|
| Americas | 2 | 2003 | 52 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 301 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2008 | 874 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 639 | 0.060 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2003 | 41 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2005 | 321 | 0.060 |
Why?
|
| Periplaneta | 1 | 2003 | 1 | 0.060 |
Why?
|
| Alanine | 1 | 2004 | 240 | 0.060 |
Why?
|
| Oils, Volatile | 1 | 2003 | 3 | 0.060 |
Why?
|
| Cyclooxygenase 1 | 1 | 2003 | 67 | 0.060 |
Why?
|
| Child | 5 | 2023 | 29154 | 0.060 |
Why?
|
| Serine Proteases | 1 | 2023 | 20 | 0.060 |
Why?
|
| Caco-2 Cells | 1 | 2023 | 158 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2005 | 587 | 0.060 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2023 | 44 | 0.060 |
Why?
|
| Ventilators, Mechanical | 1 | 2023 | 50 | 0.060 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 156 | 0.060 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 855 | 0.060 |
Why?
|
| Iron | 1 | 2006 | 376 | 0.060 |
Why?
|
| Molecular Weight | 1 | 2003 | 629 | 0.060 |
Why?
|
| Alleles | 4 | 2017 | 2437 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2007 | 419 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 866 | 0.050 |
Why?
|
| Insect Vectors | 1 | 2003 | 110 | 0.050 |
Why?
|
| Linear Models | 1 | 2005 | 1085 | 0.050 |
Why?
|
| Remission Induction | 1 | 2009 | 3569 | 0.050 |
Why?
|
| In Vitro Techniques | 3 | 2016 | 1618 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2004 | 483 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2005 | 428 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2012 | 997 | 0.050 |
Why?
|
| Attachment Sites, Microbiological | 1 | 2021 | 7 | 0.050 |
Why?
|
| Receptors, Complement 3d | 1 | 2021 | 8 | 0.050 |
Why?
|
| Interleukin-10 | 2 | 2015 | 478 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 848 | 0.050 |
Why?
|
| Hydro-Lyases | 1 | 2021 | 14 | 0.050 |
Why?
|
| Nitrites | 1 | 2002 | 61 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2008 | 1879 | 0.050 |
Why?
|
| ras Proteins | 1 | 2006 | 770 | 0.050 |
Why?
|
| Citrates | 1 | 2001 | 39 | 0.050 |
Why?
|
| Nutritive Value | 1 | 2022 | 96 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2004 | 798 | 0.050 |
Why?
|
| Peptides | 1 | 2008 | 1479 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 1546 | 0.050 |
Why?
|
| Proteomics | 1 | 2009 | 1380 | 0.050 |
Why?
|
| Indians, North American | 2 | 2017 | 87 | 0.050 |
Why?
|
| Gastric Emptying | 1 | 2001 | 94 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2022 | 123 | 0.050 |
Why?
|
| Organoids | 1 | 2024 | 287 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2003 | 483 | 0.050 |
Why?
|
| Myosin Heavy Chains | 1 | 2021 | 128 | 0.050 |
Why?
|
| Hydrogen Peroxide | 1 | 2022 | 217 | 0.050 |
Why?
|
| Hepatitis C, Chronic | 1 | 2006 | 451 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2008 | 6942 | 0.050 |
Why?
|
| Ferredoxins | 1 | 2000 | 5 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 329 | 0.050 |
Why?
|
| Sheep | 1 | 2001 | 258 | 0.050 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2000 | 21 | 0.050 |
Why?
|
| Antibodies | 2 | 2016 | 838 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 353 | 0.050 |
Why?
|
| Receptor, EphA2 | 1 | 2021 | 132 | 0.050 |
Why?
|
| Milk | 1 | 2001 | 120 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2021 | 260 | 0.050 |
Why?
|
| Human Genetics | 1 | 2019 | 5 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 16273 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2020 | 210 | 0.050 |
Why?
|
| Chromosomes, Human, Y | 1 | 2019 | 53 | 0.040 |
Why?
|
| Mice | 7 | 2015 | 34495 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 446 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2021 | 406 | 0.040 |
Why?
|
| Sequence Analysis, Protein | 2 | 2009 | 81 | 0.040 |
Why?
|
| Swine | 1 | 2023 | 1541 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2021 | 694 | 0.040 |
Why?
|
| Eye | 1 | 2021 | 301 | 0.040 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 84 | 0.040 |
Why?
|
| Amino Acids | 1 | 2022 | 728 | 0.040 |
Why?
|
| Austria | 1 | 2018 | 29 | 0.040 |
Why?
|
| Esophagitis, Peptic | 1 | 1998 | 36 | 0.040 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 1998 | 34 | 0.040 |
Why?
|
| Microscopy, Electrochemical, Scanning | 1 | 2018 | 1 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2021 | 259 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2004 | 1152 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 1998 | 60 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 4654 | 0.040 |
Why?
|
| Chemokine CCL4 | 1 | 1998 | 63 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 418 | 0.040 |
Why?
|
| Chemokine CCL3 | 1 | 1998 | 63 | 0.040 |
Why?
|
| History, Ancient | 2 | 2009 | 68 | 0.040 |
Why?
|
| Vas Deferens | 1 | 2017 | 21 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 521 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 1998 | 121 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 1656 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 1999 | 602 | 0.040 |
Why?
|
| Seminal Vesicles | 1 | 2017 | 152 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2019 | 234 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2004 | 1555 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2008 | 323 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 3719 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 709 | 0.040 |
Why?
|
| Operative Time | 1 | 2017 | 217 | 0.040 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 353 | 0.040 |
Why?
|
| Bromodeoxyuridine | 1 | 2016 | 139 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.040 |
Why?
|
| Polynesia | 2 | 2009 | 5 | 0.040 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 130 | 0.040 |
Why?
|
| Periplasm | 1 | 2015 | 7 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 403 | 0.030 |
Why?
|
| Comorbidity | 1 | 2022 | 2352 | 0.030 |
Why?
|
| Family | 1 | 2000 | 736 | 0.030 |
Why?
|
| Operon | 1 | 2015 | 53 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2006 | 2669 | 0.030 |
Why?
|
| Geographic Mapping | 1 | 2015 | 14 | 0.030 |
Why?
|
| Chromosomes | 1 | 2016 | 244 | 0.030 |
Why?
|
| Genes, Essential | 1 | 2015 | 48 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 309 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 1033 | 0.030 |
Why?
|
| Capillaries | 1 | 1995 | 99 | 0.030 |
Why?
|
| Neurosecretory Systems | 1 | 1995 | 66 | 0.030 |
Why?
|
| Keratosis, Actinic | 1 | 2015 | 37 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2008 | 4821 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2021 | 829 | 0.030 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2015 | 53 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 5687 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 276 | 0.030 |
Why?
|
| Probiotics | 1 | 2017 | 228 | 0.030 |
Why?
|
| Optical Imaging | 1 | 2016 | 157 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2017 | 575 | 0.030 |
Why?
|
| Computational Biology | 2 | 2012 | 1271 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3981 | 0.030 |
Why?
|
| Pakistan | 1 | 2014 | 77 | 0.030 |
Why?
|
| Research | 1 | 2017 | 415 | 0.030 |
Why?
|
| Protein Binding | 1 | 2021 | 3438 | 0.030 |
Why?
|
| beta Catenin | 2 | 2008 | 688 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 717 | 0.030 |
Why?
|
| Microbiological Techniques | 1 | 2014 | 40 | 0.030 |
Why?
|
| Serotonin | 1 | 1995 | 264 | 0.030 |
Why?
|
| Language | 2 | 2009 | 309 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1999 | 1910 | 0.030 |
Why?
|
| Gastric Acidity Determination | 2 | 2004 | 15 | 0.030 |
Why?
|
| Advance Care Planning | 1 | 2014 | 86 | 0.030 |
Why?
|
| Environment | 1 | 2014 | 190 | 0.030 |
Why?
|
| False Negative Reactions | 2 | 2004 | 275 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 677 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 131 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 987 | 0.030 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 2 | 2005 | 25 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2021 | 935 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 558 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 4938 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 651 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1997 | 992 | 0.030 |
Why?
|
| Prostate | 1 | 2017 | 1088 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 308 | 0.030 |
Why?
|
| Bacterial Vaccines | 2 | 2004 | 103 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2012 | 68 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 15862 | 0.030 |
Why?
|
| Bayes Theorem | 2 | 2009 | 1021 | 0.030 |
Why?
|
| Outpatients | 1 | 2014 | 462 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 2944 | 0.030 |
Why?
|
| Glutens | 1 | 2011 | 9 | 0.030 |
Why?
|
| Molluscacides | 1 | 1990 | 1 | 0.020 |
Why?
|
| Avian Myeloblastosis Virus | 1 | 1990 | 7 | 0.020 |
Why?
|
| Snails | 1 | 1990 | 4 | 0.020 |
Why?
|
| Species Specificity | 2 | 2005 | 777 | 0.020 |
Why?
|
| Sequence Analysis | 1 | 2011 | 73 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2011 | 99 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 673 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 4975 | 0.020 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1990 | 61 | 0.020 |
Why?
|
| Afghanistan | 1 | 2010 | 5 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2015 | 600 | 0.020 |
Why?
|
| Gastrins | 1 | 2010 | 55 | 0.020 |
Why?
|
| Sugar Alcohol Dehydrogenases | 1 | 1989 | 12 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 257 | 0.020 |
Why?
|
| Aldehyde Reductase | 1 | 1989 | 60 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2000 | 2819 | 0.020 |
Why?
|
| Databases, Protein | 1 | 2009 | 100 | 0.020 |
Why?
|
| Melanesia | 1 | 2009 | 3 | 0.020 |
Why?
|
| Phospholipase C beta | 1 | 2008 | 11 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2015 | 7226 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1999 | 568 | 0.020 |
Why?
|
| Population Dynamics | 1 | 2009 | 42 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 1648 | 0.020 |
Why?
|
| Methylmethacrylates | 1 | 1988 | 16 | 0.020 |
Why?
|
| Methacrylates | 1 | 1988 | 21 | 0.020 |
Why?
|
| Acrylates | 1 | 1988 | 30 | 0.020 |
Why?
|
| Caregivers | 1 | 2014 | 677 | 0.020 |
Why?
|
| Butylated Hydroxyanisole | 1 | 2008 | 2 | 0.020 |
Why?
|
| Lens, Crystalline | 1 | 1989 | 155 | 0.020 |
Why?
|
| DNA Damage | 1 | 2016 | 1954 | 0.020 |
Why?
|
| Dantrolene | 1 | 2008 | 9 | 0.020 |
Why?
|
| Australia | 1 | 2009 | 225 | 0.020 |
Why?
|
| Cytochalasin D | 1 | 2008 | 19 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 2008 | 54 | 0.020 |
Why?
|
| Thapsigargin | 1 | 2008 | 38 | 0.020 |
Why?
|
| Capsules | 1 | 1988 | 53 | 0.020 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2008 | 43 | 0.020 |
Why?
|
| Trefoil Factor-3 | 1 | 2008 | 10 | 0.020 |
Why?
|
| Peroxidase | 1 | 2008 | 132 | 0.020 |
Why?
|
| Mucin-6 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Trefoil Factor-1 | 1 | 2008 | 15 | 0.020 |
Why?
|
| Trefoil Factor-2 | 1 | 2008 | 17 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2008 | 37 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2009 | 355 | 0.020 |
Why?
|
| HMGB Proteins | 1 | 2008 | 16 | 0.020 |
Why?
|
| Mucin-2 | 1 | 2008 | 62 | 0.020 |
Why?
|
| Urban Population | 1 | 2009 | 269 | 0.020 |
Why?
|
| U937 Cells | 1 | 2008 | 171 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 2074 | 0.020 |
Why?
|
| Genistein | 1 | 2008 | 73 | 0.020 |
Why?
|
| Carcinoma | 1 | 1999 | 2578 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2008 | 198 | 0.020 |
Why?
|
| Mucin 5AC | 1 | 2008 | 75 | 0.020 |
Why?
|
| Saliva | 1 | 2009 | 231 | 0.020 |
Why?
|
| Gentamicins | 1 | 2008 | 90 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 252 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2008 | 126 | 0.020 |
Why?
|
| Hydrolysis | 2 | 2001 | 227 | 0.020 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2008 | 123 | 0.020 |
Why?
|
| Sulfones | 1 | 2008 | 143 | 0.020 |
Why?
|
| Pregnancy | 2 | 2012 | 7573 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2008 | 234 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2008 | 471 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 4758 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 1546 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 4844 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 856 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2008 | 397 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2008 | 576 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 1487 | 0.020 |
Why?
|
| Ferritins | 1 | 2006 | 151 | 0.020 |
Why?
|
| Helicobacter | 1 | 2005 | 14 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 13310 | 0.020 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2005 | 57 | 0.020 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2005 | 16 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2008 | 2027 | 0.020 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2005 | 56 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2005 | 299 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2008 | 5710 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2004 | 103 | 0.020 |
Why?
|
| Turkey | 1 | 2004 | 57 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 1764 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 4078 | 0.020 |
Why?
|
| Famotidine | 1 | 2004 | 15 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 2004 | 127 | 0.020 |
Why?
|
| Lippia | 1 | 2003 | 1 | 0.010 |
Why?
|
| Sodium Bicarbonate | 1 | 2004 | 59 | 0.010 |
Why?
|
| Buffers | 1 | 2003 | 44 | 0.010 |
Why?
|
| Social Problems | 1 | 2003 | 4 | 0.010 |
Why?
|
| Terpenes | 1 | 2003 | 34 | 0.010 |
Why?
|
| Nitriles | 1 | 2008 | 906 | 0.010 |
Why?
|
| Plant Oils | 1 | 2003 | 37 | 0.010 |
Why?
|
| Agriculture | 1 | 2003 | 37 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 644 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2003 | 110 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2005 | 551 | 0.010 |
Why?
|
| Imidazoles | 1 | 2008 | 999 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 1143 | 0.010 |
Why?
|
| Naproxen | 1 | 2002 | 27 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2017 | 5542 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2008 | 2084 | 0.010 |
Why?
|
| Dairy Products | 1 | 2001 | 38 | 0.010 |
Why?
|
| Genome | 1 | 2005 | 672 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2005 | 667 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 1399 | 0.010 |
Why?
|
| Liver Neoplasms | 2 | 2008 | 4557 | 0.010 |
Why?
|
| FMN Reductase | 1 | 2000 | 9 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 2489 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 980 | 0.010 |
Why?
|
| Cell Count | 1 | 2002 | 508 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 2000 | 125 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 2314 | 0.010 |
Why?
|
| Formamides | 1 | 1999 | 2 | 0.010 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1999 | 34 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 1823 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 354 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2006 | 1682 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 2803 | 0.010 |
Why?
|
| Lansoprazole | 1 | 1998 | 19 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 1988 | 84 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 1213 | 0.010 |
Why?
|
| Penicillins | 1 | 1998 | 143 | 0.010 |
Why?
|
| Spectrum Analysis | 1 | 1998 | 139 | 0.010 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1997 | 73 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2005 | 4307 | 0.010 |
Why?
|
| Health Status | 1 | 2000 | 590 | 0.010 |
Why?
|
| Liver | 1 | 2006 | 2961 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1997 | 557 | 0.010 |
Why?
|
| Software | 1 | 2003 | 1321 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 657 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1999 | 1544 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2000 | 1203 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2000 | 2203 | 0.010 |
Why?
|
| Patient Selection | 1 | 2000 | 2055 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 4757 | 0.010 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 1 | 1991 | 2 | 0.010 |
Why?
|
| Magnoliopsida | 1 | 1991 | 9 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1991 | 95 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1991 | 548 | 0.010 |
Why?
|
| Methylmethacrylate | 1 | 1988 | 15 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1991 | 624 | 0.010 |
Why?
|
| Tablets, Enteric-Coated | 1 | 1988 | 11 | 0.010 |
Why?
|
| Powders | 1 | 1988 | 23 | 0.010 |
Why?
|
| Solubility | 1 | 1988 | 242 | 0.010 |
Why?
|
| Rabbits | 1 | 1989 | 957 | 0.000 |
Why?
|
| Particle Size | 1 | 1988 | 182 | 0.000 |
Why?
|
| Kinetics | 1 | 1989 | 2049 | 0.000 |
Why?
|